Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Fluorescence assay to predict activity of the glycopeptide antibiotics


Here, we describe a fluorescent assay developed to study competitive binding of the glycopeptide antibiotics to live bacteria cells. This assay demonstrated that the mechanism of action of the lipoglycopeptide antibiotics strongly depends on the hydrophobicity of the substitutes, with the best antibacterial activity of the glycopeptide antibiotics equally sharing properties of binding to d-Ala–d-Ala residues of the nascent peptidoglycan and to the membrane.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2


  1. Kristóf K, et al. Significance of methicillin-teicoplanin resistant Staphylococcus haemolyticus in bloodstream infections in patients of the Semmelweis University hospitals in Hungary. Eur J Clin Microbiol Infect Dis. 2011;30:691–9.

    Article  Google Scholar 

  2. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012;10:266–78.

    Article  CAS  Google Scholar 

  3. Butler MS, Hansford Ka, Blaskovich MAT, Halai R, Cooper MA. Glycopeptide antibiotics: back to the future. J Antibiot (Tokyo). 2014;67:631–44.

    Article  CAS  Google Scholar 

  4. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action . Clin Infect Dis. 2012;54:S214–9.

    Article  CAS  Google Scholar 

  5. Blostica TM, Klepser ME. Dalbavancin: a novel long-acting lipoglycopeptide antibiotic. Formulary. 2006;41:59–73.

    CAS  Google Scholar 

  6. Charneski L, Patel PN, Sym D. Telavancin: a novel lipoglycopeptide antibiotic. Ann Pharmacother. 2009.

    Article  PubMed  Google Scholar 

  7. Zeng D, et al. Approved glycopeptide antibacterial drugs: mechanism of action and resistance. Cold Spring Harb Perspect Med. 2016.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Jarzembowski T, Jóźwik A, Wiśniewska K, Witkowski J. Flow cytometry approach study of enterococcus faecalis vancomycin resistance by detection of vancomycin@fl binding to the bacterial cells. Curr Microbiol. 2010.

    Article  PubMed  Google Scholar 

  9. Smith JR, et al. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother. 2014.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Pintér G, et al. Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study. J Med Chem. 2009;52:6053–61.

    Article  Google Scholar 

  11. Csávás, M et al. Synthesis and antibacterial evaluation of some teicoplanin pseudoaglycon derivatives containing alkyl- and arylthiosubstituted maleimides. J Antibiot (Tokyo). 2015;68:579–85.

  12. Szucs Z, et al. Synthesis and biological evaluation of lipophilic teicoplanin pseudoaglycon derivatives containing a substituted triazole function. J Antibiot (Tokyo). 2017.

    Article  Google Scholar 

  13. Chang JD, Foster EE, Thadani AN, Ramirez AJ, Kim SJ. Crossm inhibition of Staphylococcus aureus cell wall biosynthesis by desleucyl-oritavancin: a quantitative peptidoglycan composition analysis by mass spectrometry. J Bacteriol. 2017;199:1–12.

    Article  Google Scholar 

Download references


We thank Dr. M. Horsburgh for providing us with S. aureus strains from his collection. This work was supported by the Czech Health Research Council project NV15-28807A, by the project BIOCEV—Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (CZ.1.05/1.1.00/02.010) from the European Regional Development Fund in the Czech Republic, and by the EU, and co-financed by the European Regional Development Fund under the project GINOP-2.3.2 – 15-2016-00008.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Vladimir Vimberg.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vimberg, V., Gazak, R., Szűcs, Z. et al. Fluorescence assay to predict activity of the glycopeptide antibiotics. J Antibiot 72, 114–117 (2019).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links